home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
DP Tool Club 17
/
CD_ASCQ_17_101194.iso
/
vrac
/
med9408d.zip
/
M9480743.TXT
< prev
next >
Wrap
Text File
|
1994-08-27
|
2KB
|
40 lines
Document 0743
DOCN M9480743
TI Three open-label studies of oral interferon alpha in the treatment of
HIV disease.
DT 9410
AU Jordan WC; Oasis (AIDS) Clinic, Martin Luther King, Jr General
Hospital,; Drew University of Medicine and Science, Los Angeles,
California.
SO J Natl Med Assoc. 1994 Apr;86(4):257-62. Unique Identifier : AIDSLINE
MED/94315636
AB Three open-label studies were conducted in which natural human
interferon-alpha (nHuIFN-alpha) was given orally to human
immunodeficiency virus (HIV)-infected patients at a daily dosage of 150
IU for 12 months in an attempt to assess the effects of this treatment
on their CD4+ cell counts. In the first study, 110 patients received
nHuIFN-alpha, and 142 patients received nHuIFN-alpha and azidothymidine
(AZT). At 12 months, patients given nHuIFN-alpha alone had a mean
increase of 14% in their CD4+ counts, although the mean increase in
absolute CD4+ count was similar between the groups. Blacks in this study
were more likely to experience an increase in CD4+ count than other
ethnic groups (P < 0.001). In the second study, 40 black, male
homosexuals with CD4+ count between 350 and 500/mm3 were enrolled in
groups of 10 to receive either nHuIFN-alpha or AZT, or both nHuIFN-alpha
and AZT, or nothing (untreated controls). At 12 months, the mean CD4+
counts of the patients in the group given nHuIFN-alpha alone were
significantly higher than the mean CD4+ counts in both the group given
AZT alone and the untreated controls (P < 0.01). In the third study, 38
patients with CD4+ cell counts > 700/mm3 were enrolled in groups of 19,
matched by gender and ethnic group, to receive nHuIFN-alpha or nothing
(untreated controls). Patients given nHuIFN-alpha experienced a mean
increase of 12% in their CD4+ counts by the end of the 12-month
study.(ABSTRACT TRUNCATED AT 250 WORDS)
DE Administration, Oral Adult Female Human HIV
Seropositivity/ETHNOLOGY/*THERAPY Interferon-alpha/*THERAPEUTIC USE
Male CLINICAL TRIAL JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).